Transforming Cancer Treatment with Personal Genetics
MiraDx strives to improve the assessment of individual patients’ responses and toxicity profiles to specific therapies in order to radically change the meaning of personalized medicine. The company was co-founded by Joanne Weidhaas, M.D., Ph.D., and Frank Slack, Ph.D., whose cutting-edge genetic research led to the discovery of a new class of genetic biomarkers. Today, we partner with universities and clinics to utilize our genetic biomarkers to help better treat cancer.
Joanne Weidhaas, MD, PhD, MSM
Dr. Weidhaas is a co-founder of MiraDx and professor at the David Geffen School of Medicine at UCLA and head of translation research, in the Department of Radiation Oncology. Her pioneering research led to the co-discovery of the KRAS-variant, a strong predictor of cancer risk, tumor biology and treatment response. Her passion to empower individuals with meaningful information to help them take charge of their health led her to co-found MiraDx and found MiraKind. Joanne completed her oncology training at Memorial Sloan-Kettering Cancer Center in New York City and previously served as the Chief of the Breast Cancer Radiation Service at Yale Cancer Center and the Radiation Section Chief of Breast Cancer at the Yale Cancer Center. While on sabbatical at Yale, she completed an MSM at Stanford University. She moved to UCLA as Professor and Division Head, Translational Research in 2014. Her dual role as a clinician and researcher has enabled her to apply genetic breakthroughs to the benefit of her patients. She currently lives in the LA area, with her husband and three children.
Frank Slack, PhD
Frank is a co-founder of MiraDx and currently the Shields Warren Mallinckrodt Professor, Department of Pathology, and Director of the Institute for RNA Medicine, at BIDMC. His pioneering genetic research led to the discovery of let-7, one of the first microRNAs discovered, which he was able to show regulated cancer-causing genes. Dr. Slack is an internationally renowned researcher and lecturer on microRNAs, one of the fastest-growing and exciting areas of genetic research.
Board & Advisors
Andrew J. Weidhaas, JD
Board of Directors
Mary Lake Polan, MD, PhD, MPH
Board of Directors
Roy Vagelos, MD
Medical Advisory Board
Milhan Telatar, PhD
Laboratory Director
Sara Rosenthal, MBA
Advisor, Women’s Health
